09 July 2026 : Clinical Research
Preliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension
Dongde Xie ABCDEFG 1*, Mingming Deng ABCDEFG 1, Xiaoming Yang ABCDEFG 1, Jie Huang ABCDEFG 1, Xucan Hong ABCDEFG 1, Ning Xu ABCDEFG 1DOI: 10.12659/MSM.952296
Med Sci Monit 2026; 32:e952296
Table 3 Individualized medication for hypertension under pharmacogenomics guidance.
| Detection site | Genotype | Phenotype | Expected effect | Drug types | Related drugs |
|---|---|---|---|---|---|
| CYP2D6 []25 | *1/*1 | Metabolic function was normal | Normal level | β-blocker | Labelolol, aprolol, metoprolol, carvedilol, bisoprolol |
| *1/*10 | Metabolic function was slightly lower | Slightly higher | |||
| *10/*10 | Metabolic function was lower | Higher | |||
| CYP2C9 []26 | *1/*1 | Metabolic function was normal | Normal level | Angiotensin II receptor antagonist | Valsartan, losartan, irbesartan, candesartan, irbesartan |
| *1/*3 | Metabolic function was slightly lower | Slightly higher (losartan was slightly lower) | |||
| *3/*3 | Metabolic function was lower | Higher (losartan was lower) | |||
| ACE []27 | II | Enzyme activity was normal | Normal level | Angiotensin converting enzyme inhibitors | Benazepril, enalapril, fosinopril, pedoapril, ramipril |
| ID | Enzyme activity was slightly higher | Slightly higher | |||
| DD | Enzyme activity was higher | Higher | |||
| NPPA (2238T>C) []28 | TT | Sensitivity was normal | Normal level | Diuretic | Chlorothiazide, hydrochlorothiazide, benzyl fluthiazide, chlorothiazone |
| TC | Sensitivity was slightly higher | Slightly higher | |||
| CC | Sensitivity was higher | Higher | |||
| CYP3A5 []29 | *1/*1 | Metabolic function was normal | Normal level | Calcium ion antagonist | Nifedipine, felodipine, racidipine, amlodipine, cinidipine |
| *1/*3 | Metabolic function was slightly lower | Slightly higher | |||
| *3/*3 | Metabolic function was lower | Higher |